Ear Diseases ; Humans ; Male ; Meniere Disease ; Middle Aged ; Syndrome

Acute Disease ; Aorta ; Aortic Diseases/therapy* ; Humans ; Syndrome

A case of Nelson syndrome was presented. Male patient of 26 years old suffering from Cushing disease underwent an bilateral epinephrectomy, after that, Nelson syndrome developed and the patient was treated by Cobalt 60, the skin was discolored and head pain was relieved. Nelson syndrome is caused by total epinephrectomy E in Cushing disease’s patient, its clinical manifestation is typically a leader skin, head pain, high blood concentration of ACTH. The treatment of choice for this syndrome is an operation of pyfrophyse through sphenoidal bone or irradiation into hypophysal hole
Nelson Syndrome ; Cushing Syndrome ; Diseases

This study introduced the diagnosis, prognosis and the treatment of lesion that causes the digestive hemorrhage and peutzjeghers syndrome. The Diculafoy lesion commonly found in the stomach, esophagus, duodenum, intestine, large intestine and rectum with congenital cause. The treatment involved the surgery and endoscopic intervention. The peutz- jeghers syndrome manifested by polypolype in the digestive tract, skin pigment surround the mouth, lip, oral mucosa; treatment was mainly symptomatic management.
Syndrome ; Digestive System Diseases

396 patients with acute brain syndrome were admitted in Ninh Binh hospital during 1993-1999. 39 cases died (9.9%). The morbidity/mortality was the highest in 1996 (116/15). The patients were mainly children under 14 years old, and were admitted commonly in May and June. Within 125 samples of serum were tested, the positive rate with virus of Japanese encephalitis was 62.5%.
Epidemiology ; Brain Diseases ; syndrome

With a control group of 43 health persons a study was performed on 131 hypertensive patients using the test of glucose tolerance. The average similar in 2 groups. In both 2 groups, an incidence of 36,78% of metabolic syndrome was concluded, among them 41,22% were in hypertensive group and 23,26% in control. The factors occurred with high frequency were diabetes, poor tolerance with glucose, BMI ≥ 23, high triglyceride levels ans low HDL- C levels subsequently
Syndrome ; Hypertension ; Metabolic Diseases

Objectives: This study looked into the prevalence of diabetes mellitus (DM) and risks for cardiovascular and metabolic diseases among young adults with diabetes (age 20-44 years old, YOD) and late-onset DM (≥45 years old, LOD) in Filipinos. Methodology: Weighted data from 546,580 adults with DM from the 8th Philippine National Nutrition and Health Survey (NNHeS) were utilized. Differences in sociodemographic, anthropometric, clinical profiles and metabolic risks were compared between YOD and LOD. Results: The aggregated prevalence of DM is 5.43% (95%CI, 5.10–5.79), YOD were 2.64% (95% CI, 2.32–3.00) and LOD 9.85% (95%CI, 9.18–10.56). Mean age of YOD was 37,6 years, LOD 59,9 years. The YOD were mostly males (56%), with higher BMI (26.24 kg/m2 vs 25 kg/m2, p=0.002), lower mean SBP (122.41±19.17 mmHg vs 135.45±22.47 mmHg, p<0.001), more daily smokers (23% vs 14%), and alcoholic beverage drinkers (39% vs 31%). Physical activity was similar between groups (44% vs 51%, p=0.078). However, average total caloric intake (1776.78±758.38 kcal vs 1596.88±639.16 kcal, p=0.023) and carbohydrate intake (306.13±142.16 grams vs 270.53±104.74 g, p=0.014) were higher in YOD. Dietary carbohydrate proportions were higher than recommended (69% vs 68%) for both groups. Young Filipinos had higher risk to develop diabetes when they are obese II (22% vs 12%), current drinker (56% vs 37%), and current smoker (28% vs 18%). Eighty percent of YOD and LOD had metabolic syndrome (MetS). With every unit increase in age and fat intake, the odds of having MetS were raised by 5.4% (95%CI 1%–10%, p=0.029) and 1.6% (95%CI 0.04%-3%, p=0.044), respectively. Conclusion Early-onset diabetes mellitus appears to be driven by obesity, MetS and social behaviors. Modifiable risk factors can be improved early to decrease hazards to develop cardiometabolic complications.
Metabolic Syndrome ; Cardiovascular Diseases

The gastrointestinal (GI) tract is colonized by a dense community of commensal microorganisms referred to as the gut microbiota. The gut microbiota and the host have co-evolved, and they engage in a myriad of immunogenic and metabolic interactions. The gut microbiota contributes to the maintenance of host health. However, when healthy microbial structure is perturbed, a condition termed dysbiosis, the altered gut microbiota can trigger the development of various GI diseases including inflammatory bowel disease, colon cancer, celiac disease, and irritable bowel syndrome. There is a growing body of evidence suggesting that multiple intrinsic and extrinsic factors, such as genetic variations, diet, stress, and medication, can dramatically affect the balance of the gut microbiota. Therefore, these factors regulate the development and progression of GI diseases by inducing dysbiosis. Herein, we will review the recent advances in the field, focusing on the mechanisms through which intrinsic and extrinsic factors induce dysbiosis and the role a dysbiotic microbiota plays in the pathogenesis of GI diseases.
Celiac Disease ; Colon ; Colonic Neoplasms ; Diet ; Dysbiosis ; Gastrointestinal Diseases* ; Genetic Variation ; Inflammatory Bowel Diseases ; Irritable Bowel Syndrome ; Microbiota*

MicroRNAs (miRNAs) are small noncoding RNA molecules that negatively regulate gene expression via degradation or translational repression of their target messenger RNAs (mRNAs). Recent studies have clearly demonstrated that miRNAs play critical roles in several biologic processes, including cell cycle, differentiation, cell development, cell growth, and apoptosis and that miRNAs are highly expressed in regulatory T (Treg) cells and a wide range of miRNAs are involved in the regulation of immunity and in the prevention of autoimmunity. It has been increasingly reported that miRNAs are associated with various human diseases like autoimmune disease, skin disease, neurological disease and psychiatric disease. Recently, the identification of mi- RNAs in skin has added a new dimension in the regulatory network and attracted significant interest in this novel layer of gene regulation. Although miRNA research in the field of dermatology is still relatively new, miRNAs have been the subject of much dermatological interest in skin morphogenesis and in regulating angiogenesis. In addition, miRNAs are moving rapidly onto center stage as key regulators of neuronal development and function in addition to important contributions to neurodegenerative disorder. Moreover, there is now compelling evidence that dysregulation of miRNA networks is implicated in the development and onset of human neruodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, Down syndrome, depression and schizophrenia. In this review, I briefly summarize the current studies about the roles of miRNAs in various autoimmune diseases, skin diseases, psychoneurological disorders and mental stress.
Alzheimer Disease ; Apoptosis ; Autoimmune Diseases ; Autoimmunity ; Cell Cycle ; Cell Differentiation ; Depression ; Dermatology ; Down Syndrome ; Gene Expression ; Humans ; Huntington Disease ; MicroRNAs ; Morphogenesis ; Neurodegenerative Diseases ; Neurons ; Parkinson Disease ; Repression, Psychology ; RNA ; RNA, Messenger ; RNA, Small Untranslated ; Schizophrenia ; Skin ; Skin Diseases ; Tourette Syndrome

MicroRNAs (miRNAs) are small noncoding RNA molecules that negatively regulate gene expression via degradation or translational repression of their target messenger RNAs (mRNAs). Recent studies have clearly demonstrated that miRNAs play critical roles in several biologic processes, including cell cycle, differentiation, cell development, cell growth, and apoptosis and that miRNAs are highly expressed in regulatory T (Treg) cells and a wide range of miRNAs are involved in the regulation of immunity and in the prevention of autoimmunity. It has been increasingly reported that miRNAs are associated with various human diseases like autoimmune disease, skin disease, neurological disease and psychiatric disease. Recently, the identification of mi- RNAs in skin has added a new dimension in the regulatory network and attracted significant interest in this novel layer of gene regulation. Although miRNA research in the field of dermatology is still relatively new, miRNAs have been the subject of much dermatological interest in skin morphogenesis and in regulating angiogenesis. In addition, miRNAs are moving rapidly onto center stage as key regulators of neuronal development and function in addition to important contributions to neurodegenerative disorder. Moreover, there is now compelling evidence that dysregulation of miRNA networks is implicated in the development and onset of human neruodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, Down syndrome, depression and schizophrenia. In this review, I briefly summarize the current studies about the roles of miRNAs in various autoimmune diseases, skin diseases, psychoneurological disorders and mental stress.
Alzheimer Disease ; Apoptosis ; Autoimmune Diseases ; Autoimmunity ; Cell Cycle ; Cell Differentiation ; Depression ; Dermatology ; Down Syndrome ; Gene Expression ; Humans ; Huntington Disease ; MicroRNAs ; Morphogenesis ; Neurodegenerative Diseases ; Neurons ; Parkinson Disease ; Repression, Psychology ; RNA ; RNA, Messenger ; RNA, Small Untranslated ; Schizophrenia ; Skin ; Skin Diseases ; Tourette Syndrome